<DOC>
	<DOCNO>NCT00811876</DOCNO>
	<brief_summary>Study evaluate real-world effectiveness Depo-Eligard® six month treatment</brief_summary>
	<brief_title>Retrospective , Non-interventional Study Depo-Eligard® .</brief_title>
	<detailed_description>The study provide data tolerance , safety acceptance Depo-Eligard® ( leuproreline acetate ) use routine clinical practice . Data efficacy parameter testosterone , PSA level , symptom treatment failure , available collected.It reflect way Depo-Eligard® use routine clinical practice PSA , testosterone level , symptom treatment failure , use parameter treatment Prostate Cancer . Patient data collect treatment period six month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Patients prescribe DepoEligard® accordance term market authorization Patients treatment DepoEligard® least six month Written consent obtain</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Prostate cancer</keyword>
</DOC>